← Eichor
Study identifier: NCT07008664 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

Condition: Lung Cancer · Lung Cancer Screening · Healthy Volunteers (HV)  ·  Sponsor: University of Maryland, Baltimore

PhaseN/A
Planned participants750
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.

This description comes directly from the study's public registry record.

Talk to the study team

McKenzie Bedra, MPH  ·  410-553-8184  ·  McKenzie.Bedra@umm.edu

Jennifer Emel, MA  ·  410-553-8048  ·  Jennifer.Emel@umm.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Maryland Baltimore Washington Medical CenterGlen Burnie, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07008664